Introducing ‘Vertex 3.0’
Vertex CEO Reshma Kewalramani, roughly six months into her tenure, sees the storied biotech company at an inflection point, with the chance to prove that its promise extends beyond a series of pioneering medicines for cystic fibrosis.
“Vertex 1.0,” Kewalramani said in an interview with the Boston Globe yesterday, came during the company’s salad days of trying to bend medicinal chemistry into more-effective pills. The second era came in the last decade, when Vertex successfully developed what are now that standard-of-care treatments for CF. With 2020 comes “3.0,” she said, in which “Vertex moves from a CF-only company to a CF-and company.”
The ands in question are medicines for sickle-cell disease, pain, Type 1 diabetes, and muscular dystrophy, among other investigational drugs. Each is in either early or mid-stage development, but “these diseases, with all humility, I do think we are going to transform just like we did CF,” Kewalramani said.
“Vertex 1.0,” Kewalramani said in an interview with the Boston Globe yesterday, came during the company’s salad days of trying to bend medicinal chemistry into more-effective pills. The second era came in the last decade, when Vertex successfully developed what are now that standard-of-care treatments for CF. With 2020 comes “3.0,” she said, in which “Vertex moves from a CF-only company to a CF-and company.”
The ands in question are medicines for sickle-cell disease, pain, Type 1 diabetes, and muscular dystrophy, among other investigational drugs. Each is in either early or mid-stage development, but “these diseases, with all humility, I do think we are going to transform just like we did CF,” Kewalramani said.
.png)
No hay comentarios:
Publicar un comentario